- Home
- IMCC vs GNPX Comparison
IMCC vs GNPX Comparison
Compare IMCC & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCC
- GNPX
- Stock Information
- Founded
- IMCC 1980
- GNPX 2009
- Country
- IMCC Israel
- GNPX United States
- Employees
- IMCC N/A
- GNPX N/A
- Industry
- IMCC Medicinal Chemicals and Botanical Products
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- IMCC Health Care
- GNPX Health Care
- Exchange
- IMCC Nasdaq
- GNPX Nasdaq
- Market Cap
- IMCC 7.5M
- GNPX 6.1M
- IPO Year
- IMCC N/A
- GNPX 2018
- Fundamental
- Price
- IMCC $1.58
- GNPX $0.30
- Analyst Decision
- IMCC
- GNPX Strong Buy
- Analyst Count
- IMCC 0
- GNPX 1
- Target Price
- IMCC N/A
- GNPX $10.00
- AVG Volume (30 Days)
- IMCC 8.3K
- GNPX 6.0M
- Earning Date
- IMCC 03-31-2025
- GNPX 05-13-2025
- Dividend Yield
- IMCC N/A
- GNPX N/A
- EPS Growth
- IMCC N/A
- GNPX N/A
- EPS
- IMCC N/A
- GNPX N/A
- Revenue
- IMCC $37,551,778.00
- GNPX N/A
- Revenue This Year
- IMCC $22.59
- GNPX N/A
- Revenue Next Year
- IMCC $32.86
- GNPX N/A
- P/E Ratio
- IMCC N/A
- GNPX N/A
- Revenue Growth
- IMCC 10.71
- GNPX N/A
- 52 Week Low
- IMCC $1.50
- GNPX $0.22
- 52 Week High
- IMCC $8.10
- GNPX $4.09
- Technical
- Relative Strength Index (RSI)
- IMCC 36.99
- GNPX 39.82
- Support Level
- IMCC $1.50
- GNPX $0.22
- Resistance Level
- IMCC $1.84
- GNPX $0.41
- Average True Range (ATR)
- IMCC 0.14
- GNPX 0.06
- MACD
- IMCC -0.01
- GNPX -0.00
- Stochastic Oscillator
- IMCC 16.33
- GNPX 25.00
About IMCC IM Cannabis Corp.
IM Cannabis Corp is a Canada-based international medical cannabis company. It operates in the field of medical cannabis, through Focus Medical Herbs Ltd. (Focus), which holds a cultivation license to breed, grow, and supply medical cannabis products The majority of its revenues are generated from sales of medical cannabis products to customers in Israel. The remaining revenues are generated from sales of medical cannabis, as well as other products, to customers in Germany. Geographically, the majority is from Israel.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.